Cite
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
MLA
Lionel D. Lewis, et al. “Safety and Efficacy of Nivolumab in Combination with Sunitinib or Pazopanib in Advanced or Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.” Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, Oct. 2018, pp. 1–12. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....dc173dc612c24796154312f87f15907f&authtype=sso&custid=ns315887.
APA
Lionel D. Lewis, David F. McDermott, Christian Kollmannsberger, Jennifer L. Spratlin, Marc S. Ernstoff, Michael A. Carducci, Brian I. Rini, Asim Amin, Daniel Y.C. Heng, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers, Martin H. Voss, Elizabeth R. Plimack, Todd M. Bauer, & Jennifer J. Knox. (2018). Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for ImmunoTherapy of Cancer, 6(1), 1–12.
Chicago
Lionel D. Lewis, David F. McDermott, Christian Kollmannsberger, Jennifer L. Spratlin, Marc S. Ernstoff, Michael A. Carducci, Brian I. Rini, et al. 2018. “Safety and Efficacy of Nivolumab in Combination with Sunitinib or Pazopanib in Advanced or Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.” Journal for ImmunoTherapy of Cancer 6 (1): 1–12. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....dc173dc612c24796154312f87f15907f&authtype=sso&custid=ns315887.